Compare Novo Nordisk A/S (NVO) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Paycom Software Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while Paycom Software Inc trades at $232.55 (market cap $10.36B). The key difference: Novo Nordisk A/S is far larger — about 16× Paycom Software Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Paycom Software Inc for 84 Days on average.
| NVO | PAYC | |
|---|---|---|
Market Cap | $165.31B | $10.36B |
Volume | 11,432,838 | 666,294 |
Sector | Health | Technology |
52-Week High | $63.98 | $240.52 |
52-Week Low | $35.29 | $113.59 |
Typical Hold Time | 116 Days | 84 Days |
Enterprise Value | $179.56B | $11.15B |
Dividend Yield | 4.71% | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Paycom Software (PAYC) trades at $232.22, up 3.86% today, reflecting strong momentum after recent earnings beats and raised 2026 guidance. The stock shows bullish technical signals, with support near $226 and resistance at $232. Fundamentally, PAYC maintains robust profitability with a 22.78% net margin and 10% revenue growth in Q2 2026, though its P/E of 24.33 suggests a premium valuation. Positive sentiment is driven by institutional buying and analyst coverage, with 47% recommending Buy.
Outlook: PAYC's earnings momentum and operational efficiency support upside, but risks include premium valuation pressure and labor market sensitivity. The consensus price target of $207.75 implies caution, yet raised guidance and buybacks provide tailwinds. Investors should weigh strong execution against macroeconomic headwinds affecting payroll demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
